Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Title
Intervention Indication Therapeutic Area Year Actions
Lisocabtagene Maraleucel (Liso-Cel) for Relapsed/Refractory Diffuse Large B-cell Lymphoma Lisocabtagene maraleucel (Liso-cel; JCAR017) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2018 View  |  Download
Lisocabtagene maraleucel for relapsed or refractory, aggressive B-cell non-Hodgkin Lymphoma – second line Lisocabtagene maraleucel (Liso-cel; JCAR017) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2020 View  |  Download
Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma - second-line Lisocabtagene maraleucel (Liso-cel; JCAR017) Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma , Non-Hodgkin lymphoma (NHL) , Primary mediastinal large B-cell lymphoma (PMBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Lisocabtagene maraleucel for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma Lisocabtagene maraleucel (Liso-cel; JCAR017) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications